TMCnet News

Global Anti-Parkinson's Drugs Market 2018: Analysis & Forecasts (2013-2022) - Major Players Abbvie, Mylan Laboratories, Valeant Pharmaceuticals and Novartis are Profiled - ResearchAndMarkets.com
[March 12, 2018]

Global Anti-Parkinson's Drugs Market 2018: Analysis & Forecasts (2013-2022) - Major Players Abbvie, Mylan Laboratories, Valeant Pharmaceuticals and Novartis are Profiled - ResearchAndMarkets.com


The "Anti-Parkinson's Drugs: Global Markets to 2022" report has been added to ResearchAndMarkets.com's offering.

This research report categorizes the anti-Parkinson's drugs market by type. Product types include low dopaminergic, dopamine agonists, enzyme inhibitors and other anti-Parkinson's medications.

This report includes:

  • 95 data tables
  • An overview of the global market for anti-Parkinson's drugs and their future demand
  • Analyses of global market trends, with data from 2013-2017, and projections of compound annual growth rates (CAGRs) through 2022
  • Analyses of the major factors and technological advances such as biomarkers, 3D printed drugs, mobile applications and wearable technologies in the monitoring and treatment of Parkinson's disease
  • Discussion of the major segments of the anti-Parkinson's drugs, i.e., dopaminergic drugs, dopamine agonists, enzyme inhibitors and other anti-Parkinson's medications
  • Company profiles of the major players in the market, including AbbVie, Mylan Laboratories, Valeant Pharmaceuticals and Novartis

Key Findings:

  • The global anti-Parkinson's drugs market should reach $5.7 billionby 2022 from $4.2 billion in 2017 at a compound annual growth rate (CAGR) of 6.1%, from 2017 to 2022.
  • Asia Pacific anti-Parkinson's drugs market is expected to grow from $1 billion in 2017 to $1.4 billion in 2022 at a CAGR of 6.4% for the period 2017-2022.
  • North American anti-Parkinson's drugs market is expected to grow from $1.3 billion in 2017 to $1.8 billion in 2022 at a CAGR of 7% for the period 2017-2022.



Companies Mentioned:

  • Abbvie
  • Boehringer Ingelheim
  • F. Hoffmann-La Roche AG
  • Novartis AG
  • UCB SA

Key Topics Covered:


1 Introduction

2 Summary and Highlights

3 Anti-Parkinson's Drugs Market Characteristics

4 Anti-Parkinson's Drugs Market Size and Growth

5 Anti-Parkinson's Drugs Market Trends and Strategies

6 PESTLE Analysis

7 Anti-Parkinson's Drugs Market Segmentation

8 Anti-Parkinson's Drugs Market Regional and Country Analysis

9 Global Anti-Parkinson's Drugs Market Comparison with Macro Economic Factors

10 Asia-Pacific Anti-Parkinson's Drugs Market

11 Asia-Pacific Anti-Parkinson's Drugs Market: Country Analysis

12 Western Europe Anti-Parkinson's Drugs Market

13 Western Europe Anti-Parkinson's Drugs Market: Country Analysis

14 Eastern Europe Anti-Parkinson's Drugs Market

15 Eastern Europe Anti-Parkinson's Drugs Market: Country Analysis

16 North America Anti-Parkinson's Drugs Market

17 North America Anti-Parkinson's Drugs Market: Country Analysis

18 South America Anti-Parkinson's Drugs Market

19 South America Anti-Parkinson's Drugs Market: Country Analysis

20 Middle East Anti-Parkinson's Drugs Market

21 Africa Anti-Parkinson's Drugs Market

22 Anti-Parkinson's Drugs Market Customer Information

23 Anti-Parkinson's Drugs Market Competitive Landscape

24 Key Mergers and Acquisitions in the Anti-Parkinson's Drugs Market

For more information about this report visit https://www.researchandmarkets.com/research/wz43xb/global?w=4


[ Back To TMCnet.com's Homepage ]